Actualités id2725.html
In development: Guidance, quality standards and advice
Tue, 28 Jan 2025 12:54:00 GMT
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] Technology appraisal guidance 22 May 2025 Erdafitinib for treating metastatic or unresectable FGFR ...
In consultation: Guidance and quality standards
Sat, 08 Feb 2025 00:50:00 GMT
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] Draft guidance Technology appraisal guidance 25 February 2025 Spesolimab for treating generalised ...